- 询价
- 2026年05月29日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫类型：
IgG1 (Igh-4a allotype)
- 细胞形态：
淋巴样
- 库存：
大量
- 运输方式：
冻存运输
- 生长状态：
悬浮生长
- 物种来源：
小鼠
- 是否是肿瘤细胞：
0
- ATCC Number：
HB-187™
| Designations: | 162-46.2 [Trop-2] | ||
| Depositors: | AM Stall | ||
| Isotype: | IgG1 (Igh-4a allotype) | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | suspension | ||
| Organism: | Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma) | ||
| Morphology: | lymphoblast |
||
| Source: | Cell Type: hybridoma: B lymphocyte; | ||
| Cellular Products: | immunoglobulin; monoclonal antibody; against the trop-2 antigen of human trophoblasts cells and choriocarcinomas | ||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Tumorigenic: | Yes | ||
| Comments: | Animals were immunized with BeWo cells (ATCC CCL-98 ). Spleen cells were fused with P3-NSI/1-Ag4-1 myeloma cells. The antibody defines an antigen that is expressed on trophoblasts and choriocarcinoma cells but not on blood cells or other tumor cells. Tested and found negative for ectromelia virus (mousepox). |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. |
||
| Subculturing: | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
||
| References: | 1309: Lipinski M, et al. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 78: 5147-5150, 1981. PubMed: 7029529 | ||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验.1 14.9 14.7 14.6 14.5 14.5 14.4 14.3 14.2 14.2 14.1 14.0 13.9 3 4 10.6 9.98 9.60 9.36 9.20 9.07 8.98 8.90 8.84 8.75 8.66 8.56 8.46 8.36 8.26 4 5 8.43 7.76 7.39 7.16 6.98 6.85 6.76 6.68 6.62 6.52 6.43 6.33 6.23 6.12 6.01 5 6 7.26 6.60 5.23
1．检验目的 检测血清Trop-I主要是用于急性心肌梗塞等疾病的鉴别诊断，可以动态观察相关疾病的发生发展过程、疗效及预后评估。 2．方法原理 采用了美国雅培公司的专利技术——微粒子酶免疫分析（MEIA），即以anti-Trop-I包被微粒子（○M-Ab）与标本中的Trop-I形成○M-Ab-Ag复合物，当复合物被转移到纤维杯上时，微粒子就不可逆地结合到纤维杯表面的玻璃纤维上，并与加入的碱性磷酸酶标记anti-Trop-I结合，洗去未结合的游离物质，加入底物
XBB.1.5 毒株的传播力为何这么强？北大曹云龙团队最新研究揭示相关机制
。这一结果对指导疫苗研发等具有重要意义。 图片来源：bioRxiv 主要研究内容 在本研究中，该团队使用基于水疱性口炎病毒 (Vesicular Stomatitis Virus, VSV) 的假病毒进行中和试验，评估了在 BA.1、BA.5 或 BF.7 突破性感染 (BTI) 之前接受过 3 剂 CoronaVac 疫苗的康复人群血浆对 XBB.1.5 的中和滴度。其中一组 BA.5 BTI 患者接受了至少两剂量的 BNT162b2 或 mRNA-1273 也纳入了分析。 研究结果表明
技术资料暂无技术资料 索取技术资料
